

Francesco Cortiula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3697633/publications.pdf>

Version: 2024-02-01

35
papers

387
citations

1040056

9
h-index

794594

19
g-index

36
all docs

36
docs citations

36
times ranked

1055
citing authors

#	ARTICLE	IF	CITATIONS
1	Physical exercise at the crossroad between muscle wasting and the immune system: implications for lung cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 55-67.	7.3	12
2	Immunotherapy in NSCLC Patients with Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7068.	4.1	12
3	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021, 146, 145-154.	2.8	8
4	A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Diagnostics</i> , 2020, 10, 765.	2.6	7
5	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	2.4	1
6	Seven Shades of Black Thoughts: COVID-19 and Its Psychological Consequences on Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1357.	2.8	15
7	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. <i>Drugs and Aging</i> , 2020, 37, 677-689.	2.7	1
8	416P A novel prognostic tool based on lymphocyte ratios in patients with stage III colon cancer. <i>Annals of Oncology</i> , 2020, 31, S418.	1.2	0
9	842P Carboplatin-induced thrombocytopenia in ovarian cancer: A focus on predictive factors. <i>Annals of Oncology</i> , 2020, 31, S631.	1.2	0
10	P-266 LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: The LINE study. <i>Annals of Oncology</i> , 2020, 31, S176-S177.	1.2	0
11	Managing COVID-19 in the oncology clinic and avoiding the distraction effect. <i>Annals of Oncology</i> , 2020, 31, 553-555.	1.2	136
12	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 661-668.	3.7	21
13	P-246 Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer. <i>Annals of Oncology</i> , 2020, 31, S170.	1.2	0
14	Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16118-e16118.	1.6	1
15	The impact of prior chemotherapy (PrC) on immunotherapy outcomes in non-small cell lung cancer (NSCLC) patients: Real data from a mono-institutional study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21639-e21639.	1.6	1
16	Management of immune-related adverse events: A single-center retrospective analysis in a real-world scenario.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15163-e15163.	1.6	0
17	Liquid biopsy in clinical practice of non-small cell lung cancer (NSCLC): A multi-institutional experience. <i>Annals of Oncology</i> , 2019, 30, v644.	1.2	1
18	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	6.4	24

#	ARTICLE	IF	CITATIONS
19	SUN-PO094: The Role of Nutritional Interventions in Surgically Treated Pancreatic Cancer Patients: Comparative Efficacy in a Network Meta-Analysis (NMA). <i>Clinical Nutrition</i> , 2019, 38, S93-S94.	5.0	0
20	Emerging therapies in malignant pleural mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102815.	4.4	17
21	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	2.3	7
22	The <sc>IMPACT</sc> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 368-377.	7.3	61
23	Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach. <i>Annals of Translational Medicine</i> , 2019, 7, 14-14.	1.7	11
24	Clinico-pathological and molecular characterization of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Annals of Oncology</i> , 2018, 29, v58.	1.2	1
25	Monocyte-to-lymphocyte ratio in metastatic colorectal cancer: Prognostic role evaluation and cut-off definition. <i>Annals of Oncology</i> , 2018, 29, viii180.	1.2	0
26	The SENECA study: Prognostic role of serum biomarkers in elderly metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2018, 29, viii197.	1.2	0
27	Determinants of oncologist's choice in offering drug holidays during first line therapy for patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, viii197-viii198.	1.2	0
28	Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario. <i>Annals of Oncology</i> , 2018, 29, viii426.	1.2	1
29	The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, viii193.	1.2	0
30	Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2018, 140, 559-568.	2.9	9
31	Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Journal of Clinical Oncology</i> , 2018, 36, 3590-3590.	1.6	4
32	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 609-619.	3.1	33
33	Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients. <i>Annals of Oncology</i> , 2017, 28, vi94.	1.2	0
34	First-line platinum-based chemotherapy in elderly patients with NSCLC: determinants of therapeutic choice and outcome. <i>Annals of Oncology</i> , 2017, 28, vi61.	1.2	0
35	In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy. , 0, , .		0